← Back to front page
Oceania · General news · The Australian

Neurizon advances Regimen I into treatment extension alongside $3.7m R&D drawdown

Published by The Australian · Australia 9 h ago
Neurizon advances Regimen I into treatment extension alongside $3.7m R&D drawdown
The Australian

Detailed summary

The first participant in Regimen I of Neurizon Therapeutics’ Phase 2/3 ALS Platform Trial has completed the 36-week randomised controlled trial (RCT) phase and transitioned into…

Read the full article on The Australian Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.theaustralian.com.au)

Also worth reading